Tenax Therapeutics Advances Phase 3 LEVEL Trial Results Presentation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Newsfilter
- Clinical Trial Results Announcement: Tenax Therapeutics has announced that it will present results from the LEVEL clinical trial on August 29, 2026, at the European Society of Cardiology Congress in Munich, Germany, which is expected to significantly impact treatment for heart failure patients.
- Trial Design and Scale: The LEVEL trial is a registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in over 230 patients, with enrollment completed in March 2026, demonstrating strong trial design and execution capabilities.
- Primary Endpoint Metrics: A prespecified Blinded Sample Size Re-estimation in December 2025 indicated that the trial is powered at over 90% to detect a 25-meter change in 6-minute walk distance (6MWD), providing robust support for the reliability of the results.
- Market Potential and Strategic Significance: Tenax holds global rights to develop and commercialize levosimendan for the treatment of the most prevalent form of pulmonary hypertension, and successful outcomes could fill a significant market gap, greatly enhancing the company's competitive position in the cardiology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TENX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TENX
Wall Street analysts forecast TENX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.260
Low
20.00
Averages
25.00
High
30.00
Current: 16.260
Low
20.00
Averages
25.00
High
30.00
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenax Therapeutics Advances Phase 3 LEVEL Trial Results Presentation
- Clinical Trial Results Announcement: Tenax Therapeutics has announced that it will present results from the LEVEL clinical trial on August 29, 2026, at the European Society of Cardiology Congress in Munich, Germany, which is expected to significantly impact treatment for heart failure patients.
- Trial Design and Scale: The LEVEL trial is a registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in over 230 patients, with enrollment completed in March 2026, demonstrating strong trial design and execution capabilities.
- Primary Endpoint Metrics: A prespecified Blinded Sample Size Re-estimation in December 2025 indicated that the trial is powered at over 90% to detect a 25-meter change in 6-minute walk distance (6MWD), providing robust support for the reliability of the results.
- Market Potential and Strategic Significance: Tenax holds global rights to develop and commercialize levosimendan for the treatment of the most prevalent form of pulmonary hypertension, and successful outcomes could fill a significant market gap, greatly enhancing the company's competitive position in the cardiology sector.
See More
Tenax Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: Tenax Therapeutics reported a Q1 GAAP EPS of -$0.35, beating expectations by $0.05, indicating an improvement in financial performance that may boost investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Tenax had cash and cash equivalents of $118.8 million, bolstered by proceeds from warrant exercises during the quarter, ensuring sufficient funding for future operations.
- Funding Outlook: The company expects its cash reserves to sustain operations through at least Q1 2028, providing a solid financial foundation for R&D and market expansion, which could enhance future growth prospects.
- Executive Appointment: Tenax appointed Thomas Staab as CFO, aiming to leverage his extensive financial management experience to optimize the company's financial strategy and further advance its position in the biopharmaceutical sector.
See More
Tenax Therapeutics Appoints New CFO
- New CFO Appointment: Tenax Therapeutics has appointed Thomas R. Staab II as CFO effective May 11, 2026, replacing interim CFO Thomas McGauley, with Staab bringing over 25 years of financial leadership experience in the healthcare sector, which is expected to enhance the company's financial management capabilities.
- Equity Incentive Plan: The company also announced inducement equity awards tied to Staab's appointment, including 10,000 restricted stock units and options to purchase 450,000 common shares, aimed at attracting and retaining executive talent, thereby strengthening financial stability and market competitiveness.
- Positive Market Reaction: Ahead of the CFO appointment, Cantor expressed a bullish outlook on Tenax, suggesting that the company has potential for positive performance in the upcoming pivotal readout, which could boost investor confidence and drive stock price appreciation.
- Historical Performance Review: Historical earnings data for Tenax Therapeutics indicates that despite facing market challenges, the company possesses certain growth potential, with future strategic directions focusing on enhancing financial transparency and optimizing capital structure.
See More
Tenax Therapeutics Appoints New CFO
- Executive Change: Tenax Therapeutics has appointed Thomas Staab as Chief Financial Officer, effective May 11, 2026, replacing Thomas McGauley, indicating a strategic shift in the company's leadership team.
- Extensive Experience: Staab brings over 25 years of leadership experience in management and corporate finance within the healthcare sector, having most recently served as CFO and Secretary of LENSAR, which is expected to enhance Tenax's financial management capabilities.
- Predecessor's Performance: Prior to this role, Staab was Senior Vice President, CFO, and Treasurer at BioCryst Pharmaceuticals, where he provided critical financial strategic support during his tenure.
- Market Reaction: Tenax Therapeutics saw a premarket increase of 0.88%, reaching $13.8, reflecting positive market expectations regarding the new CFO's potential impact.
See More
Tenax Therapeutics Receives Overweight Rating from Cantor Fitzgerald
- Rating Upgrade: Cantor Fitzgerald initiated coverage on Tenax Therapeutics (TENX) with an Overweight rating and a $35 price target, which is expected to drive stock price appreciation and reflects market recognition of its potential value.
- Clinical Trial Outlook: Analyst Olivia Saunders noted that Tenax is set to release topline data from its Phase 3 LEVEL study for TNX-103 in Q3 2026, with the potential for the company's valuation to double or triple if results are statistically significant, indicating a high-risk, high-reward investment opportunity.
- Market Potential: Saunders projected over $1.5 billion in peak sales for TNX-103, which could become the first FDA-approved therapy for pulmonary hypertension due to heart failure with preserved ejection fraction, marking a significant breakthrough in treatment options.
- Commercial Prospects: Should the LEVEL trial yield positive results, TNX-103 could create a franchise worth over $3 billion, further solidifying Tenax's market position in the biopharmaceutical sector and attracting increased investor interest.
See More
Tenax Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Tenax Therapeutics reported a Q4 GAAP EPS of -$0.38, beating expectations by $0.03, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Reserves Status: As of December 31, 2025, Tenax's cash and cash equivalents stood at $97.6 million, which is expected to fund the company's operations through 2027, ensuring the continuity of its R&D projects.
- Future Potential Outlook: Despite the current negative earnings, Tenax is viewed as a speculative buy due to improving clinical trial results, which could lead to a higher valuation for the company.
- Market Evaluation: Seeking Alpha's quant rating on Tenax Therapeutics reflects market interest in its future developments, prompting investors to closely monitor the company's performance in upcoming quarters and its impact on stock price.
See More
Tenax Therapeutics Advances Phase 3 LEVEL Trial Results Presentation
- Clinical Trial Results Announcement: Tenax Therapeutics has announced that it will present results from the LEVEL clinical trial on August 29, 2026, at the European Society of Cardiology Congress in Munich, Germany, which is expected to significantly impact treatment for heart failure patients.
- Trial Design and Scale: The LEVEL trial is a registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in over 230 patients, with enrollment completed in March 2026, demonstrating strong trial design and execution capabilities.
- Primary Endpoint Metrics: A prespecified Blinded Sample Size Re-estimation in December 2025 indicated that the trial is powered at over 90% to detect a 25-meter change in 6-minute walk distance (6MWD), providing robust support for the reliability of the results.
- Market Potential and Strategic Significance: Tenax holds global rights to develop and commercialize levosimendan for the treatment of the most prevalent form of pulmonary hypertension, and successful outcomes could fill a significant market gap, greatly enhancing the company's competitive position in the cardiology sector.
See More
Tenax Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: Tenax Therapeutics reported a Q1 GAAP EPS of -$0.35, beating expectations by $0.05, indicating an improvement in financial performance that may boost investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Tenax had cash and cash equivalents of $118.8 million, bolstered by proceeds from warrant exercises during the quarter, ensuring sufficient funding for future operations.
- Funding Outlook: The company expects its cash reserves to sustain operations through at least Q1 2028, providing a solid financial foundation for R&D and market expansion, which could enhance future growth prospects.
- Executive Appointment: Tenax appointed Thomas Staab as CFO, aiming to leverage his extensive financial management experience to optimize the company's financial strategy and further advance its position in the biopharmaceutical sector.
See More
Tenax Therapeutics Appoints New CFO
- New CFO Appointment: Tenax Therapeutics has appointed Thomas R. Staab II as CFO effective May 11, 2026, replacing interim CFO Thomas McGauley, with Staab bringing over 25 years of financial leadership experience in the healthcare sector, which is expected to enhance the company's financial management capabilities.
- Equity Incentive Plan: The company also announced inducement equity awards tied to Staab's appointment, including 10,000 restricted stock units and options to purchase 450,000 common shares, aimed at attracting and retaining executive talent, thereby strengthening financial stability and market competitiveness.
- Positive Market Reaction: Ahead of the CFO appointment, Cantor expressed a bullish outlook on Tenax, suggesting that the company has potential for positive performance in the upcoming pivotal readout, which could boost investor confidence and drive stock price appreciation.
- Historical Performance Review: Historical earnings data for Tenax Therapeutics indicates that despite facing market challenges, the company possesses certain growth potential, with future strategic directions focusing on enhancing financial transparency and optimizing capital structure.
See More
Tenax Therapeutics Appoints New CFO
- Executive Change: Tenax Therapeutics has appointed Thomas Staab as Chief Financial Officer, effective May 11, 2026, replacing Thomas McGauley, indicating a strategic shift in the company's leadership team.
- Extensive Experience: Staab brings over 25 years of leadership experience in management and corporate finance within the healthcare sector, having most recently served as CFO and Secretary of LENSAR, which is expected to enhance Tenax's financial management capabilities.
- Predecessor's Performance: Prior to this role, Staab was Senior Vice President, CFO, and Treasurer at BioCryst Pharmaceuticals, where he provided critical financial strategic support during his tenure.
- Market Reaction: Tenax Therapeutics saw a premarket increase of 0.88%, reaching $13.8, reflecting positive market expectations regarding the new CFO's potential impact.
See More
Tenax Therapeutics Receives Overweight Rating from Cantor Fitzgerald
- Rating Upgrade: Cantor Fitzgerald initiated coverage on Tenax Therapeutics (TENX) with an Overweight rating and a $35 price target, which is expected to drive stock price appreciation and reflects market recognition of its potential value.
- Clinical Trial Outlook: Analyst Olivia Saunders noted that Tenax is set to release topline data from its Phase 3 LEVEL study for TNX-103 in Q3 2026, with the potential for the company's valuation to double or triple if results are statistically significant, indicating a high-risk, high-reward investment opportunity.
- Market Potential: Saunders projected over $1.5 billion in peak sales for TNX-103, which could become the first FDA-approved therapy for pulmonary hypertension due to heart failure with preserved ejection fraction, marking a significant breakthrough in treatment options.
- Commercial Prospects: Should the LEVEL trial yield positive results, TNX-103 could create a franchise worth over $3 billion, further solidifying Tenax's market position in the biopharmaceutical sector and attracting increased investor interest.
See More
Tenax Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Tenax Therapeutics reported a Q4 GAAP EPS of -$0.38, beating expectations by $0.03, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Reserves Status: As of December 31, 2025, Tenax's cash and cash equivalents stood at $97.6 million, which is expected to fund the company's operations through 2027, ensuring the continuity of its R&D projects.
- Future Potential Outlook: Despite the current negative earnings, Tenax is viewed as a speculative buy due to improving clinical trial results, which could lead to a higher valuation for the company.
- Market Evaluation: Seeking Alpha's quant rating on Tenax Therapeutics reflects market interest in its future developments, prompting investors to closely monitor the company's performance in upcoming quarters and its impact on stock price.
See More
